“Persistent Toxic Cardiomyopathy in Young Her2-Positive Breast Cancer Patient After Anthracyclines, Taxanes, and Trastuzumab Biosimilar”

https://pubmed.ncbi.nlm.nih.gov/38095178

A young patient developed persistent toxic cardiomyopathy after receiving anthracyclines, taxanes, and trastuzumab biosimilar for Her2-positive breast cancer, with atypical presentation and possible additional causative factors.